Market Overview

What To Make Of Alexion's New FDA Approval

What To Make Of Alexion's New FDA Approval
Related ALXN
20 Stocks Moving In Wednesday's Pre-Market Session
The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering
A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed (Seeking Alpha)

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) were trading higher by more than 5 percent early Tuesday morning after the U.S. Food and Drug Administration approved its therapy called Soliris (eculizumab) for the treatment of adults with generalized myasthenia gravis (gMG).

GMG represents a $1 billion, plus, opportunity for Alexion and targets approximately a subset of patients with antibodies to the o the acetylcholine receptor (anti-AChR+), which accounts for 75 percent of all gMG patients, Cowen's Eric Schmidt said in a research report. The therapy is expected to be reserved for use in patients who cannot tolerate alternative medications.

Schmidt maintains an Outperform rating on Alexion's stock with an unchanged $180 price target and re-iterates the stock as a "top large cap pick."


Approval of the therapy was based on the company's phase 3 REGAIN trial in which Soliris "narrowly missed" the trial's primary endpoint, the analyst also said. But on the product's label, the FDA accepted a different analysis that allowed the trial to achieve statistical significance while multiple secondary endpoints were successful as well.

"Most investors were optimistic for approval in gMG," the analyst also said in the report. "This is based upon Alexion's characterization of FDA discussions as constructive (no AdCom required) and prior EMA approval (granted in August). Nonetheless, given the missed primary endpoint, FDA approval was not guaranteed, and we expect a bit of a relief rally in the stock."

Finally, interest in gMG is expected to build ahead of a "robust launch" and given a price tag of more than $700,000 per year, the U.S. opportunity could "easily exceed" $1 billion with upside potential from international markets the company plans to commercialize in the future.

Related Links:

29 Top Stock Ideas For October And Beyond

Attention Biotech Investors, Here's Your PDUFA Primer For October
Image Credit: Public Domain, via Wikimedia Commons

Latest Ratings for ALXN

Oct 2018CitigroupMaintainsBuyBuy
Oct 2018Morgan StanleyMaintainsOverweightOverweight
Sep 2018CitigroupMaintainsBuyBuy

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: CowenAnalyst Color Biotech News FDA Analyst Ratings Movers General Best of Benzinga


Related Articles (ALXN)

View Comments and Join the Discussion!

Latest Ratings

XECImperial CapitalDowngrades35.0
SSTIImperial CapitalUpgrades49.0
AVDLoop CapitalUpgrades29.0
FCREYDeutsche BankUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Benzinga's Top Upgrades, Downgrades For October 24, 2017

MoviePass Surpasses 600,000 Subscriptions; Helios And Matheson Investors Are Loving It